Bicocca Open Archive

Logo unimib boa
ROMERIO, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.993
NA - Nord America 2.828
AS - Asia 2.346
SA - Sud America 282
Continente sconosciuto - Info sul continente non disponibili 134
AF - Africa 54
OC - Oceania 27
Totale 11.664
Salva come PNG Salva come JPEG
Nazione #
SE - Svezia 3.759
US - Stati Uniti d'America 2.680
IT - Italia 1.185
SG - Singapore 562
VN - Vietnam 560
CN - Cina 377
DE - Germania 301
HK - Hong Kong 211
BR - Brasile 202
RU - Federazione Russa 175
IN - India 137
GB - Regno Unito 98
KR - Corea 95
FR - Francia 88
CA - Canada 87
BD - Bangladesh 83
NL - Olanda 71
ES - Italia 58
JP - Giappone 58
ID - Indonesia 54
IE - Irlanda 45
PL - Polonia 45
FI - Finlandia 35
PK - Pakistan 31
IR - Iran 28
AR - Argentina 27
AU - Australia 26
MX - Messico 23
BE - Belgio 22
DK - Danimarca 22
IQ - Iraq 22
TR - Turchia 21
ZA - Sudafrica 21
CO - Colombia 15
AT - Austria 14
SA - Arabia Saudita 14
UA - Ucraina 14
MY - Malesia 13
PH - Filippine 12
EC - Ecuador 11
LT - Lituania 11
CL - Cile 10
UZ - Uzbekistan 10
CH - Svizzera 9
CR - Costa Rica 9
MA - Marocco 8
PT - Portogallo 8
TW - Taiwan 8
IL - Israele 7
JM - Giamaica 6
PY - Paraguay 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
GR - Grecia 5
JO - Giordania 5
AL - Albania 4
EG - Egitto 4
ET - Etiopia 4
GT - Guatemala 4
KZ - Kazakistan 4
LB - Libano 4
NG - Nigeria 4
NP - Nepal 4
DO - Repubblica Dominicana 3
EE - Estonia 3
GA - Gabon 3
PR - Porto Rico 3
TN - Tunisia 3
AM - Armenia 2
BB - Barbados 2
GP - Guadalupe 2
HN - Honduras 2
HU - Ungheria 2
KE - Kenya 2
KH - Cambogia 2
MK - Macedonia 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
RO - Romania 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TH - Thailandia 2
A1 - Anonimo 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
Totale 11.520
Salva come PNG Salva come JPEG
Città #
Stockholm 3.728
Milan 430
Ashburn 351
Singapore 337
Frankfurt am Main 252
San Jose 237
Ho Chi Minh City 184
Hong Kong 182
Council Bluffs 154
Hanoi 131
Los Angeles 99
Ann Arbor 90
Hefei 70
Washington 69
Rome 68
New York 63
Santa Clara 57
Beijing 53
Dallas 52
Seoul 50
Chicago 48
Jakarta 43
Columbus 42
Dublin 42
Tokyo 41
Boardman 36
São Paulo 36
Toronto 34
Phoenix 33
Buffalo 32
Turin 30
Amsterdam 28
Chandler 28
Florence 27
Jeju City 27
Bologna 25
Naples 23
Helsinki 22
Hyderabad 22
Shanghai 22
Houston 21
London 21
Atlanta 20
Figino 20
Maastricht 20
Warsaw 20
Brisbane 18
Copenhagen 18
Philadelphia 18
Sassuolo 17
The Dalles 17
Can Tho 16
Da Nang 16
Orem 16
Chennai 15
Lauterbourg 15
Madison 15
New Delhi 15
Paris 15
Brooklyn 14
Johannesburg 14
Montreal 14
Brescia 13
Denver 13
Ha Long 13
Monza 13
Biên Hòa 12
San Giuliano Terme 12
Seattle 12
Boston 11
Haiphong 11
Moscow 11
Baghdad 10
Hải Dương 10
Poplar 10
Tashkent 10
Kent 9
Lahore 9
Lappeenranta 9
Novate Milanese 9
Nuremberg 9
Parma 9
Princeton 9
Vienna 9
Austin 8
Biloxi 8
Brussels 8
Cerdanyola del Vallès 8
Como 8
Desio 8
Medellín 8
Mexico City 8
Munich 8
Quận Bình Thạnh 8
San Francisco 8
San José 8
Barnet 7
Cedar Rapids 7
Guangzhou 7
Hangzhou 7
Totale 8.030
Salva come PNG Salva come JPEG
Nome #
Representative secondary PET micro and nanoplastics via ethylene glycol fragmentation (EGF): Physicochemical and immuno-toxicological properties 2.048
Validating Natural Compounds as Toll-Like Receptor 4 (TLR4) Antagonists: Experimental Challenges and Therapeutic Perspectives 1.981
Synthesis and Biological Characterization of TLR4 Agonists as Innovative Vaccine Adjuvants 866
NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR 512
Vibrational spectroscopy coupled with machine learning sheds light on the cellular effects induced by rationally designed TLR4 agonists 435
Highly Selective SERCA2a Activators: Preclinical Development of a Congeneric Group of First-in-Class Drug Leads against Heart Failure 397
Synthetic Glycolipids as Molecular Vaccine Adjuvants: Mechanism of Action in Human Cells and in Vivo Activity 375
Potentiation of fluoroquinolone and macrolide activities by efflux pump inhibitory effect on Staphylococcus aureus and Streptococcus pyogenes of new benzyl piperazinyl lysine derivatives 356
Increasing the Chemical Variety of Small-Molecule-Based TLR4 Modulators: An Overview 354
New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as Vaccine Adjuvants 338
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases 323
Impact of Toll-like Receptor 4 (TLR4) chemical modulation by small- molecular antagonists in rare inflammatory-fibrotic diseases 313
Design, Synthesis and characterization of synthetic and natural derived TLR4 antagonists 312
Towards more efficient synthetic immunomodulators: biological characterization and mechanism of action of monosaccharide-derived TLR4 agonists 304
Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of Enterococcus faecium-binding Antibodies 284
Development of a New Vaccine Adjuvant System Based on the Combination of the Synthetic TLR4 Agonist FP20 and a Synthetic QS-21 Variant 259
Overcoming Challenges in Chemical Glycosylation to Achieve Innovative Vaccine Adjuvants Possessing Enhanced TLR4 Activity 257
Cleaner synthesis of preclinically validated vaccine adjuvants 205
Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge 205
Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection 198
Study on the impact of Toll-like Receptor 4 (TLR4) modulation in rare inflammatory-fibrotic diseases 182
Functional impact of Toll-like Receptor 4 (TLR4) modulation in lung fibrosis-associated fibroblasts 168
Developing New Toll-Like Receptor 4 (TLR4) Modulators As Innovative And Inexpensive Vaccine Adjuvants 124
Design, Synthesis and Biological Evaluation of New Glycolipid-Based Toll-Like Receptor 4 (TLR4) Modulators 94
Developing New Toll-Like Receptor 4 (TLR4) Modulators as Innovative and Inexpensive Vaccine Adjuvants 92
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW, GLYCOLIPID-BASED TOLL-LIKE RECEPTOR 4 (TLR4) MODULATORS 85
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 75
NEW SMALL MOLECULES AS TLR4 MODULATORS: SYNTHESIS AND BIOLOGICAL CHARACTERIZATION 74
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 72
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 67
Design, synthesis and Biological evaluation of New, glycolipid-based Toll-Like Receptor 4 (TLR4) Modulators 66
Harnessing Immunity: Synthesis of New Modulators of Toll-like Receptor 4 (TLR4) 56
HARNESSING IMMUNITY: SYNTHESIS OF NEW MODULATORS OF TOLL-LIKE RECEPTOR 4 (TLR4) 53
Design, synthesis and biological evaluation of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy. 37
Design, synthesis and biological evaluation of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy. 34
Design, synthesis and biological evaluation of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy. 32
Design and synthesis of a new Toll Like Receptor 4 agonist-based Antibody Drug Conjugate for cancer immunotherapy 31
Totale 11.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.516
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.516
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022118 0 0 0 0 0 0 0 28 14 12 16 48
2022/2023501 43 58 42 35 51 50 12 88 21 42 26 33
2023/2024536 52 19 39 31 52 65 44 23 53 42 42 74
2024/20251.451 70 89 120 101 104 76 77 64 131 194 148 277
2025/20267.530 557 251 225 404 320 164 392 184 346 4.197 155 335
2026/20271.528 207 201 512 608 0 0 0 0 0 0 0 0
Totale 11.664